MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations

por Kerstjens, Mark, Driessen, Emma M.C., Willekes, Merel, Pinhanços, Sandra S., Schneider, Pauline, Pieters, Rob, Stam, Ronald W.
Publicado 2016

Identification of Genes Transcriptionally Responsive to the Loss of MLL Fusions in MLL-Rearranged Acute Lymphoblastic Leukemia

por van der Linden, Marieke H., Seslija, Lidija, Schneider, Pauline, Driessen, Emma M. C., Castro, Patricia Garrido, Stumpel, Dominique J. P. M., van Roon, Eddy, de Boer, Jasper, Williams, Owen, Pieters, Rob, Stam, Ronald W.
Publicado 2015